Sponsor:
Ascletis Pharma (China) Co., Limited
Code:
NCT07743450
Conditions
Obesity
Overweight
Chronic Weight Management
Type 2 Diabetes Mellitus
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
ASC30 tablets A1
Placebo
Brief summary:
Conditions
Obesity
Overweight
Chronic Weight Management
Type 2 Diabetes Mellitus
Study ID
NCT07743450
Start date
Aug, 2026
Status verified date
Jul, 2026
Completion date
Jul, 2028
Anticipated
Primary completion date
Jul, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
1560 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: ASC30 Cohort 1
experimental: ASC30 Cohort 2
experimental: ASC30 Cohort 3
placebo comparator: Placebo Cohort 4
Interventions
ASC30 tablets A1
Placebo
Primary outcome measure
Locations
AURORA-2 Clinical Site
Recruiting
Phoenix, Arizona, United States, 85020
Contacts
Ascletis Recruiting
clinicaltrials@ascletis.comAURORA-2 Clinical Site
Recruiting
Melbourne, Florida, United States, 32934-8172
Contacts
Ascletis Recruiting
clinicaltrials@ascletis.comAURORA-2 Clinical Site
Recruiting
The Villages, Florida, United States, 32162
Contacts
Ascletis Recruiting
clinicaltrials@ascletis.comAURORA-2 Clinical Site
Recruiting
Evansville, Indiana, United States, 47714-7513
Contacts
Ascletis Recruiting
clinicaltrials@ascletis.comAURORA-2 Clinical Site
Recruiting
Austin, Texas, United States, 78744-1645
Contacts
Ascletis Recruiting
clinicaltrials@ascletis.comAURORA-2 Clinical Site
Recruiting
San Antonio, Texas, United States, 78229-3272
Contacts
Ascletis Recruiting
clinicaltrials@ascletis.comSponsor
Ascletis Pharma (China) Co., Limited
Last update posted
Aug 14, 2026
Last verified
Jul, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Ascletis Pharma (China) Co., Limited on 2026-08-14.